Fut, nem toboroz1. fázis
A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers
Key facts
- Where
- Dresden és Essen, NémetországSee the 2 sites
- Phase
- 1. fázis
Where in Németország
- Technische Universität DresdenDresden, NémetországNo longer taking part
- Universitaetsklinikum Essen (AoR)Essen, NémetországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharma AG
- Trial code
- EU 2022-502381-25-01
- Record updated
- 2026. augusztus 3.